Retatrutide: The Triple Agonist — What Phase II Data Shows

Why a Third Receptor Matters

Semaglutide targets GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide targets all three: GLP-1, GIP, and the glucagon receptor. Each additional receptor target addresses a fundamentally different aspect of energy balance and metabolism.

The glucagon receptor is the critical differentiator. While GLP-1 and GIP primarily reduce energy intake (appetite suppression, delayed gastric emptying, improved insulin signalling), glucagon receptor activation increases energy expenditure — the output side of the equation.

This is significant because all weight-loss interventions eventually face the problem of metabolic adaptation — the body reduces its energy expenditure in response to caloric restriction, creating a plateau. By directly stimulating thermogenesis and hepatic fat oxidation through the glucagon receptor, Retatrutide may partially counteract this adaptation.

The Glucagon Receptor: What It Does

Glucagon is often thought of simply as insulin's opposite — it raises blood sugar. But its metabolic effects are far broader:

Thermogenesis

Glucagon receptor activation stimulates energy expenditure through multiple mechanisms:

• Brown adipose tissue (BAT) activation — Glucagon signalling increases heat production in brown fat
• Hepatic thermogenesis — The liver generates heat as it oxidises fatty acids
• Increased metabolic rate — Measured as increased resting energy expenditure

Hepatic Fat Oxidation

This is perhaps the most clinically significant effect. The glucagon receptor is the primary signal for the liver to:

• Release and burn stored fat (hepatic lipids)
• Reduce de novo lipogenesis (the creation of new fat)
• Promote ketogenesis (fat-derived fuel production)

The implications for non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatotic liver disease (MASLD) are enormous — conditions that affect an estimated 25–30% of the global adult population.

Appetite Regulation

Glucagon itself has modest appetite-suppressing effects, which complement the powerful appetite suppression from GLP-1 and GIP. The three-receptor approach creates a more comprehensive appetite regulation signal than either single or dual agonism.

The Phase II Trial: Published in the New England Journal of Medicine (2023)

Study Design

• Population: 338 adults with BMI 30–50 (or ≥27 with at least one comorbidity), without diabetes
• Design: Randomised, double-blind, placebo-controlled, dose-finding study
• Doses tested: 1 mg, 4 mg, 8 mg, 12 mg (weekly SubQ injection)
• Duration: 48 weeks
• Published: Jastreboff AM, et al. N Engl J Med. 2023;389(6):514–526.

Results

Dose	Weight Loss (%)	≥5% Responders	≥10% Responders	≥15% Responders
1 mg	8.7%	64%	43%	25%
4 mg	17.1%	93%	75%	68%
8 mg	22.8%	100%	93%	82%
12 mg	24.2%	100%	93%	93%
Placebo	2.1%	19%	9%	5%

Key Observations

The weight-loss curve had not plateaued at 48 weeks. This is critically important. At the end of the study, participants on the 8 mg and 12 mg doses were still losing weight — the trajectory was steep and continuing downward. This suggests that the eventual weight loss at 72 or 96 weeks would be significantly higher than 24.2%.

For comparison:

• Semaglutide 2.4 mg achieved ~15% at 68 weeks (STEP 1)
• Tirzepatide 15 mg achieved ~22.5% at 72 weeks (SURMOUNT-1)
• Retatrutide 12 mg achieved ~24.2% at only 48 weeks — with the curve still declining

If the trajectory continued at the same rate to 72 weeks, projections suggest weight loss in the range of 28–30% — approaching bariatric surgery outcomes.

Liver Fat Reduction

One of the most striking findings from the Phase II data was the effect on hepatic steatosis (fatty liver):

• Participants with elevated liver fat at baseline showed reductions exceeding 80% in hepatic fat content at the 8 mg and 12 mg doses
• Many participants achieved complete resolution of fatty liver — hepatic fat content dropped below the diagnostic threshold for NAFLD

This effect is driven predominantly by the glucagon receptor component and represents a potential therapeutic breakthrough for MASLD/NAFLD — conditions with no currently approved pharmacological treatment.

Comparison at Equivalent Timepoints

To make a fair comparison, we need to look at what each compound achieved at similar durations:

Compound	Weight Loss at ~24 Weeks	Weight Loss at ~48 Weeks
Semaglutide 2.4 mg	~10%	~14% (interpolated)
Tirzepatide 15 mg	~15%	~20% (interpolated)
Retatrutide 12 mg	~17%	~24.2%

At every equivalent timepoint, Retatrutide outperforms both predecessors. The gap widens over time, likely due to the glucagon-mediated thermogenic effect counteracting metabolic adaptation.

Safety and Tolerability

GI Side Effects

The GI side effect profile was broadly similar to other GLP-1-class compounds:

• Nausea: 16–26% across dose groups (vs. 4% placebo)
• Diarrhoea: 14–22%
• Constipation: 6–12%
• Vomiting: 8–13%

Most events were mild to moderate and occurred during dose escalation phases. Discontinuation due to adverse events was relatively low (~5% across dose groups).

Unique Considerations

• Heart rate increase: Small increases in resting heart rate (2–4 bpm) were observed, consistent with the thermogenic effect. This was not associated with cardiovascular adverse events in the trial.
• No clinically significant hypoglycaemia was reported in non-diabetic participants.
• Lipid improvements: Significant reductions in triglycerides and LDL cholesterol were observed.

Phase III Outlook

Eli Lilly (the developer) initiated Phase III trials in 2023–2024. The programme includes:

• Weight management trials in non-diabetic adults (similar to SURMOUNT)
• Type 2 diabetes trials
• MASLD/NAFLD trials — where the glucagon component gives Retatrutide a unique therapeutic advantage
• Obstructive sleep apnoea trials

If Phase III confirms Phase II results — which is typical for this drug class — Retatrutide could receive FDA approval for weight management as early as 2026–2027.

Dosing Protocol (Based on Phase II)

The Phase II dose-escalation schedule:

Week	Dose
1–4	0.5 mg
5–8	2.0 mg
9–12	4.0 mg
13–16	8.0 mg
17+	12.0 mg

As with all GLP-1-class compounds, do not rush titration. The 0.5 mg and 2.0 mg phases are acclimation doses designed to minimise GI side effects. Most meaningful weight loss begins at the 4.0 mg level and accelerates significantly at 8.0 mg and 12.0 mg.

Who Should Consider Retatrutide?

Best Candidates

• Significant weight to lose (BMI ≥35+) — Retatrutide's superior efficacy is most meaningful for those with the most weight to lose
• Fatty liver disease — The glucagon-mediated hepatic fat reduction is unmatched by any other current compound
• Previous GLP-1 plateau — If you've maximised results on Semaglutide or Tirzepatide, Retatrutide's additional mechanism may restart progress
• Metabolic syndrome — The triple mechanism addresses insulin resistance, dyslipidaemia, and hepatic steatosis simultaneously

Who Might Not Need It

• Moderate weight loss goals (<15%) — Semaglutide or Tirzepatide may be sufficient and have more safety data
• Cardiovascular risk is primary concern — Semaglutide's SELECT trial data is unmatched; Retatrutide has no CV outcomes data yet
• Risk-averse individuals — Phase II data is promising but limited; Phase III trials will provide more robust safety evidence

The Bigger Picture

Retatrutide represents the natural evolution of incretin-based pharmacotherapy: from single to dual to triple agonism, each generation addressing more of the complex biology underlying obesity and metabolic dysfunction.

The addition of the glucagon receptor is not just incremental — it addresses a fundamentally different aspect of energy balance (expenditure) that previous compounds did not target directly. This may explain why the weight-loss curve hadn't plateaued at 48 weeks, and why the liver fat data was so dramatic.

We're watching Phase III closely. In the meantime, Retatrutide is available through Mito Labs for those who want early access to what may be the most effective weight-loss compound ever developed.